Mohammadjavad Sotoudeheian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammadjavad Sotoudeheian has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Seyed-Mohamad-Sadegh Mirahmadi
Department of General Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
8 shared publications - Hamidreza Pazoki-Toroudi
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
6 shared publications Amir M. Sadeghian
School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 shared publications- Marjan Mokhtare
Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
4 shared publications Mohammad Pirhayati
School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 shared publicationsReza Azarbad
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
4 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Preprints.org
Longitudinal Monitoring of Clinically Significant Liver Fibrosis in MASLD in the Era of Novel Therapeutics: Challenges, Reproducibility, and Clinical Utility of Non-Invasive Tests
Resmetirom and semaglutide are approved for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis. Guidance increasingly relies on non-invasive tests (NITs) rather than repeat biopsy to monitor response. Serial changes in FIB-4, vibration-controlled transient elastography (VCTE) and magnetic resonance elastography are prognostic for fibrosis progression and liver-related events. However, short-term variability is substantial. VCTE stiffness showed a reproducibility coefficient above 55%, whereas enhanced liver fibrosis (ELF) was markedly more stable. The consensus 30% stiffness-reduction threshold therefore lies within measurement noise. Weight loss and falling aminotransferases may shift NITs independently of fibrosis regression, and FIB-4–stiffness discordance affects about 30% of patients. Serial NITs are valuable prognostic tools but insufficient as stand-alone response measures. Standardised acquisition, variability-aware thresholds and paired complementary tests are advisable pending validation against histology and clinical outcomes.
- 13 November 2026
- Published by MDPI AG in Preprints.org
Open AccessLongitudinal Monitoring of Clinically Significant Liver Fibrosis in MASLD in the Era of Novel Therapeutics: Challenges, Reproducibility, and Clinical Utility of Non-Invasive Tests
Resmetirom and semaglutide are approved for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis. Guidance increasingly relies on non-invasive tests (NITs) rather than repeat biopsy to monitor response. Serial changes in FIB-4, vibration-controlled transient elastography (VCTE) and magnetic resonance elastography are prognostic for fibrosis progression and liver-related events. However, short-term variability is substantial. VCTE stiffness showed a reproducibility coefficient above 55%, whereas enhanced liver fibrosis (ELF) was markedly more stable. The consensus 30% stiffness-reduction threshold therefore lies within measurement noise. Weight loss and falling aminotransferases may shift NITs independently of fibrosis regression, and FIB-4–stiffness discordance affects about 30% of patients. Serial NITs are valuable prognostic tools but insufficient as stand-alone response measures. Standardised acquisition, variability-aware thresholds and paired complementary tests are advisable pending validation against histology and clinical outcomes.
- 12 October 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2) , 288
The hepato-thyroid axis in male obesity: unraveling inter-organ crosstalk through non-invasive biomarkers
- 12 October 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2) , 288
The hepato-thyroid axis in male obesity: unraveling inter-organ crosstalk through non-invasive biomarkers
- Open Access
- 18 September 2026
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 78 (1) , 69
An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors
Background: Acute heart failure (AHF) is a significant cardiovascular syndrome characterized by either new-onset heart failure (HF) or acutely decompensated heart failure (ADHF), typically presenting with systemic and pulmonary congestion. The European Society of Cardiology has reinforced the importance of early guideline-directed medical therapy (GDMT) initiation and individualized decongestive strategies. This article explores current knowledge of AHF pathophysiology. The simplified hemodynamic paradigm previously used to explain AHF has been replaced over the past few decades by a more complex network of interacting mechanisms. Main text: The clinical presentation of AHF reflects a heterogeneous combination of cardiac abnormalities and systemic pathophysiological processes rather than a single disease entity. Despite overlapping clinical presentations, AHF arises from diverse underlying conditions and pathophysiological mechanisms. Left ventricular systolic or diastolic dysfunction elevates filling pressures, contributing to increased preload and afterload, which in turn promotes pulmonary congestion. End-organ dysfunction may result from the combined effects of venous congestion, impaired perfusion, and neurohormonal and inflammatory activation. Despite advances, limited progress in acute management may contribute to persistently poor outcomes in AHF patients. Conclusion: Initial management of AHF commonly includes intravenous diuretics for patients with congestion, while vasodilators and other therapies are selected according to congestion status, perfusion, blood pressure, hemodynamic profile, clinical phenotype, and the predominant underlying pathophysiological mechanism. This review examines pathophysiological processes contributing to AHF onset and progression, highlighting clinical implications and therapeutic targets.
- 18 September 2026
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 78 (1) , 69
Open AccessAn integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors
Background: Acute heart failure (AHF) is a significant cardiovascular syndrome characterized by either new-onset heart failure (HF) or acutely decompensated heart failure (ADHF), typically presenting with systemic and pulmonary congestion. The European Society of Cardiology has reinforced the importance of early guideline-directed medical therapy (GDMT) initiation and individualized decongestive strategies. This article explores current knowledge of AHF pathophysiology. The simplified hemodynamic paradigm previously used to explain AHF has been replaced over the past few decades by a more complex network of interacting mechanisms. Main text: The clinical presentation of AHF reflects a heterogeneous combination of cardiac abnormalities and systemic pathophysiological processes rather than a single disease entity. Despite overlapping clinical presentations, AHF arises from diverse underlying conditions and pathophysiological mechanisms. Left ventricular systolic or diastolic dysfunction elevates filling pressures, contributing to increased preload and afterload, which in turn promotes pulmonary congestion. End-organ dysfunction may result from the combined effects of venous congestion, impaired perfusion, and neurohormonal and inflammatory activation. Despite advances, limited progress in acute management may contribute to persistently poor outcomes in AHF patients. Conclusion: Initial management of AHF commonly includes intravenous diuretics for patients with congestion, while vasodilators and other therapies are selected according to congestion status, perfusion, blood pressure, hemodynamic profile, clinical phenotype, and the predominant underlying pathophysiological mechanism. This review examines pathophysiological processes contributing to AHF onset and progression, highlighting clinical implications and therapeutic targets.
- 14 July 2026
- Published by Bentham Science Publishers Ltd. in The International Journal of Gastroenterology and Hepatology Diseases
- Vol. 05 (1) , 1-9
Correlation between the Atherogenic Index of Plasma, Lipoprotein Combine Index, and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score in Metabolic Dysfunction-associated Steatotic Liver Disease
Introduction: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is closely associated with an increased risk of Atherosclerotic Cardiovascular Disease (ASCVD). Dyslipidemia plays a central role in this link, and composite lipid indices such as the Atherogenic Index of Plasma (AIP) and the Lipoprotein Combine Index (LCI) have emerged as potential integrative markers of cardiovascular risk. To evaluate the association of AIP and LCI with the 10-year ASCVD risk score in adults with MASLD. Methods: In this cross-sectional study, data from 1,592 adults, including 973 individuals with MASLD, were analyzed. Associations between lipid indices and ASCVD risk were assessed using Spearman correlation and multiple linear regression models. Analyses were adjusted for sex, body mass index, tobacco and alcohol use, hypertension, diabetes, and fibrosis burden assessed by the FIB-4 score. Results: Compared with controls, individuals with MASLD had significantly higher median AIP (0.23 vs. −0.02, p<0.0001), LCI (20.81 vs. 10.47, p<0.0001), and ASCVD risk scores (10.80% vs. 8.10%, p<0.0001). Within the MASLD group, both AIP (ρ = 0.192, p<0.0001) and LCI (ρ = 0.108, p = 0.0008) showed positive correlations with ASCVD risk. In regression analyses, AIP remained a significant predictor in crude and partially adjusted models, whereas LCI emerged as an independent predictor only in the fully adjusted model (β = 0.0478, p = 0.0002). The final model explained 48.4% of the variance in ASCVD risk (R² = 0.4837). Discussion: Although both indices were associated with ASCVD risk, their modest correlations suggest limited standalone predictive power, consistent with previous reports. Conclusion: AIP and LCI are associated with higher ASCVD risk in patients with MASLD. LCI demonstrates a robust independent association after comprehensive adjustment, supporting its potential role as an integrative marker for cardiovascular risk stratification in this population.
- 14 July 2026
- Published by Bentham Science Publishers Ltd. in The International Journal of Gastroenterology and Hepatology Diseases
- Vol. 05 (1) , 1-9
Correlation between the Atherogenic Index of Plasma, Lipoprotein Combine Index, and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score in Metabolic Dysfunction-associated Steatotic Liver Disease
Introduction: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is closely associated with an increased risk of Atherosclerotic Cardiovascular Disease (ASCVD). Dyslipidemia plays a central role in this link, and composite lipid indices such as the Atherogenic Index of Plasma (AIP) and the Lipoprotein Combine Index (LCI) have emerged as potential integrative markers of cardiovascular risk. To evaluate the association of AIP and LCI with the 10-year ASCVD risk score in adults with MASLD. Methods: In this cross-sectional study, data from 1,592 adults, including 973 individuals with MASLD, were analyzed. Associations between lipid indices and ASCVD risk were assessed using Spearman correlation and multiple linear regression models. Analyses were adjusted for sex, body mass index, tobacco and alcohol use, hypertension, diabetes, and fibrosis burden assessed by the FIB-4 score. Results: Compared with controls, individuals with MASLD had significantly higher median AIP (0.23 vs. −0.02, p<0.0001), LCI (20.81 vs. 10.47, p<0.0001), and ASCVD risk scores (10.80% vs. 8.10%, p<0.0001). Within the MASLD group, both AIP (ρ = 0.192, p<0.0001) and LCI (ρ = 0.108, p = 0.0008) showed positive correlations with ASCVD risk. In regression analyses, AIP remained a significant predictor in crude and partially adjusted models, whereas LCI emerged as an independent predictor only in the fully adjusted model (β = 0.0478, p = 0.0002). The final model explained 48.4% of the variance in ASCVD risk (R² = 0.4837). Discussion: Although both indices were associated with ASCVD risk, their modest correlations suggest limited standalone predictive power, consistent with previous reports. Conclusion: AIP and LCI are associated with higher ASCVD risk in patients with MASLD. LCI demonstrates a robust independent association after comprehensive adjustment, supporting its potential role as an integrative marker for cardiovascular risk stratification in this population.
- 1 June 2026
- Published by Bentham Science Publishers Ltd. in The International Journal of Gastroenterology and Hepatology Diseases
- Vol. 05, 1-13
Relationship between Helicobacter pylori Infection and Metabolic Scores in Morbid Obese Subjects with Metabolic Dysfunction-associated Steatotic Liver Disease
Introduction: The interplay between Helicobacter pylori (H. pylori) infection and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with morbid obesity remains unclear. This study aimed to investigate associations between H. pylori infection, surrogate markers of insulin resistance, and MASLD in a well-characterized cohort. Methods: In this secondary analysis of 444 adults with morbid obesity, H. pylori status was determined histologically from gastric biopsies. MASLD was assessed via liver biopsy in 93 patients. Metabolic indices, including TyG, TyG-BMI, Atherogenic Index of Plasma (AIP), and METS-IR, were calculated from fasting laboratory data. Statistical analyses included correlation analyses and restricted cubic spline (RCS) modeling. Results: Among participants, 343 subjects were included in the analysis, where 30% had type-2 diabetes, and 18% had MASLD. No significant differences in TyG, TyG-BMI, AIP, or METS-IR were observed between H. pylori-positive and -negative groups, or between MASLD subgroups stratified by H. pylori status. Correlation analyses showed negligible associations between infection status and metabolic scores. RCS analyses suggested non-linear trends, with higher TyG and TyG-BMI values modestly increasing MASLD probability in H. pylori-positive patients, though these did not reach statistical significance. Discussion: H. pylori infection may modestly increase MASLD risk, acting as a cofactor that amplifies metabolic dysfunction, particularly in obesity. However, evidence is heterogeneous, causality remains unproven, and effect sizes are small. Future mechanistic and interventional studies are needed to clarify its role and potential for targeted therapy. Conclusion: In adults with morbid obesity, H. pylori infection was not significantly associated with surrogate markers of insulin resistance.
- 1 June 2026
- Published by Bentham Science Publishers Ltd. in The International Journal of Gastroenterology and Hepatology Diseases
- Vol. 05, 1-13
Relationship between Helicobacter pylori Infection and Metabolic Scores in Morbid Obese Subjects with Metabolic Dysfunction-associated Steatotic Liver Disease
Introduction: The interplay between Helicobacter pylori (H. pylori) infection and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with morbid obesity remains unclear. This study aimed to investigate associations between H. pylori infection, surrogate markers of insulin resistance, and MASLD in a well-characterized cohort. Methods: In this secondary analysis of 444 adults with morbid obesity, H. pylori status was determined histologically from gastric biopsies. MASLD was assessed via liver biopsy in 93 patients. Metabolic indices, including TyG, TyG-BMI, Atherogenic Index of Plasma (AIP), and METS-IR, were calculated from fasting laboratory data. Statistical analyses included correlation analyses and restricted cubic spline (RCS) modeling. Results: Among participants, 343 subjects were included in the analysis, where 30% had type-2 diabetes, and 18% had MASLD. No significant differences in TyG, TyG-BMI, AIP, or METS-IR were observed between H. pylori-positive and -negative groups, or between MASLD subgroups stratified by H. pylori status. Correlation analyses showed negligible associations between infection status and metabolic scores. RCS analyses suggested non-linear trends, with higher TyG and TyG-BMI values modestly increasing MASLD probability in H. pylori-positive patients, though these did not reach statistical significance. Discussion: H. pylori infection may modestly increase MASLD risk, acting as a cofactor that amplifies metabolic dysfunction, particularly in obesity. However, evidence is heterogeneous, causality remains unproven, and effect sizes are small. Future mechanistic and interventional studies are needed to clarify its role and potential for targeted therapy. Conclusion: In adults with morbid obesity, H. pylori infection was not significantly associated with surrogate markers of insulin resistance.
- 21 April 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (4) , 481-495
MORGAS ( MOR tality OR iented G lucose, A ge, S moking, and S tent S core) predicts mortality after percutaneous coronary intervention
Percutaneous coronary intervention (PCI) remains a cornerstone therapy for acute coronary syndromes and stable ischaemic heart disease, with million procedures performed annually worldwide [1]. How...
- 21 April 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (4) , 481-495
MORGAS ( MOR tality OR iented G lucose, A ge, S moking, and S tent S core) predicts mortality after percutaneous coronary intervention
Percutaneous coronary intervention (PCI) remains a cornerstone therapy for acute coronary syndromes and stable ischaemic heart disease, with million procedures performed annually worldwide [1]. How...
- 1 December 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (5) , 1-2
Untapped potential of efruxifermin in lean MASH
- 1 December 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (5) , 1-2
Untapped potential of efruxifermin in lean MASH
- Open Access
- 28 November 2025
- Published by MDPI AG in Preprints.org
Multispecialty Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Optimizing Cardiometabolic Risk
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a rapidly expanding global clinical challenge, closely intertwined with obesity, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular complications. Given the convergence of metabolic, hepatic and cardiac pathways, an integrated clinical strategy is increasingly essential. This review highlights how coordinated management across various specialties can refine risk stratification, improve diagnostic accuracy, and enhance long-term outcomes for patients with MASLD. The growing epidemiological burden is paralleled by escalating risks of heart failure, arrhythmias and progressive liver injury. Shared mechanisms including insulin resistance, systemic inflammation and lipotoxicity reinforce the need for comprehensive evaluations using non-invasive fibrosis scores, cardiometabolic biomarkers and structured surveillance protocols. Evidence supports the incorporation of lifestyle interventions, GLP-1 receptor agonists, SGLT2 inhibitors and tailored cardiometabolic monitoring within multidisciplinary clinics. Despite barriers such as heterogeneous referral patterns and limited cross-specialty coordination, interdisciplinary models consistently demonstrate superior early detection and more precise therapeutic planning. Moving forward, standardized follow-up pathways, longitudinal risk-based surveillance, and AI-assisted prediction tools may substantially improve personalized care and reduce morbidity in this high-risk population.
- 28 November 2025
- Published by MDPI AG in Preprints.org
Open AccessMultispecialty Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Optimizing Cardiometabolic Risk
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a rapidly expanding global clinical challenge, closely intertwined with obesity, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular complications. Given the convergence of metabolic, hepatic and cardiac pathways, an integrated clinical strategy is increasingly essential. This review highlights how coordinated management across various specialties can refine risk stratification, improve diagnostic accuracy, and enhance long-term outcomes for patients with MASLD. The growing epidemiological burden is paralleled by escalating risks of heart failure, arrhythmias and progressive liver injury. Shared mechanisms including insulin resistance, systemic inflammation and lipotoxicity reinforce the need for comprehensive evaluations using non-invasive fibrosis scores, cardiometabolic biomarkers and structured surveillance protocols. Evidence supports the incorporation of lifestyle interventions, GLP-1 receptor agonists, SGLT2 inhibitors and tailored cardiometabolic monitoring within multidisciplinary clinics. Despite barriers such as heterogeneous referral patterns and limited cross-specialty coordination, interdisciplinary models consistently demonstrate superior early detection and more precise therapeutic planning. Moving forward, standardized follow-up pathways, longitudinal risk-based surveillance, and AI-assisted prediction tools may substantially improve personalized care and reduce morbidity in this high-risk population.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Reviews in Clinical and Experimental Pharmacology
- Vol. 20 (4) , 301-321
The Role of Metformin in Modifying Ferroptosis to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: A Narrative Review
Fatty liver disease (FLD) is a well-known metabolic disorder associated with hepatic steatosis and tissue lipid accumulation. Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent and challenging condition that is linked to obesity, diabetes, and other metabolic disorders. MAFLD, previously called NAFLD or nonalcoholic fatty liver disease, is associated with pathological changes in liver tissue. In recent decades, there has been a growing interest in the potential of metformin, a commonly used medication for type-2 diabetes, to help treat MAFLD. Metformin has shown promising potential in treating MAFLD through its ability to modify ferroptosis, a novel form of programmed cell death. In this critical review, we explain the current knowledge about MAFLD, the potential role of ferroptosis in its pathogenesis, and the mechanisms by which metformin may modulate ferroptosis in the context of MAFLD. Additionally, evidence supporting the usage of metformin in treating MAFLD is explained. Overall, this review explains the potential of metformin as a novel therapeutic approach for MAFLD by targeting ferroptosis and provides valuable insights for future research in this area.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Reviews in Clinical and Experimental Pharmacology
- Vol. 20 (4) , 301-321
The Role of Metformin in Modifying Ferroptosis to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: A Narrative Review
Fatty liver disease (FLD) is a well-known metabolic disorder associated with hepatic steatosis and tissue lipid accumulation. Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent and challenging condition that is linked to obesity, diabetes, and other metabolic disorders. MAFLD, previously called NAFLD or nonalcoholic fatty liver disease, is associated with pathological changes in liver tissue. In recent decades, there has been a growing interest in the potential of metformin, a commonly used medication for type-2 diabetes, to help treat MAFLD. Metformin has shown promising potential in treating MAFLD through its ability to modify ferroptosis, a novel form of programmed cell death. In this critical review, we explain the current knowledge about MAFLD, the potential role of ferroptosis in its pathogenesis, and the mechanisms by which metformin may modulate ferroptosis in the context of MAFLD. Additionally, evidence supporting the usage of metformin in treating MAFLD is explained. Overall, this review explains the potential of metformin as a novel therapeutic approach for MAFLD by targeting ferroptosis and provides valuable insights for future research in this area.
- Open Access
- 28 October 2025
- Published by MDPI AG in Preprints.org
Albumin-Bilirubin Score and De Ritis Ratio in Assessing Disease Severity in Intrahepatic Cholestasis of Pregnancy
Background: Intrahepatic cholestasis of pregnancy (ICP) is associated with an increased risk of adverse perinatal outcomes. Simple prognostic biomarkers are needed for risk stratification. The Albumin-Bilirubin (ALBI) score and Aspartate Aminotransferase to Alanine Aminotransferase ratio (De Ritis) are established liver function indices, but their comparative utility for predicting adverse perinatal outcomes in ICP remains inadequately explored.This study aimed to evaluate and compare the prognostic performance of the ALBI score and the De Ritis ratio for predicting ICP and adverse perinatal outcomes.Methods: A retrospective study was conducted utilizing a publicly available dataset comprising 100 pregnant women with a diagnosis of ICP. The ALBI score and De Ritis ratio were calculated from serum biomarkers. Univariate and multivariable logistic regression were used to assess associations, presented as odds ratios (OR) with 95% confidence intervals (CI). Predictive performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, reporting the area under the curve (AUC), sensitivity, and specificity.Results: In univariate analysis, the ALBI score was a significant predictor of adverse outcomes (OR=20.54, p<0.001), while the De Ritis ratio was not (OR=0.78, p=0.42). The ALBI score demonstrated significantly superior discriminatory power (AUC=0.712). In multivariable models adjusting for gestational age, maternal age, ALP, and GGT, the ALBI score remained a strong, independent predictor (fully adjusted OR=21.65, p=0.006), whereas the De Ritis ratio was consistently non-significant. A model combining both scores showed good predictive performance (AUC=0.714), which was significantly enhanced to an excellent level (AUC=0.845) after full adjustment for clinical covariates.Conclusion: The ALBI score is a significant and independent predictor of ICP and adverse perinatal outcomes in the pregnancy, demonstrating good prognostic utility. In contrast, the De Ritis ratio showed no meaningful predictive value. The ALBI score could serve as a useful clinical tool for risk assessment in this patient population.
- 28 October 2025
- Published by MDPI AG in Preprints.org
Open AccessAlbumin-Bilirubin Score and De Ritis Ratio in Assessing Disease Severity in Intrahepatic Cholestasis of Pregnancy
Background: Intrahepatic cholestasis of pregnancy (ICP) is associated with an increased risk of adverse perinatal outcomes. Simple prognostic biomarkers are needed for risk stratification. The Albumin-Bilirubin (ALBI) score and Aspartate Aminotransferase to Alanine Aminotransferase ratio (De Ritis) are established liver function indices, but their comparative utility for predicting adverse perinatal outcomes in ICP remains inadequately explored.This study aimed to evaluate and compare the prognostic performance of the ALBI score and the De Ritis ratio for predicting ICP and adverse perinatal outcomes.Methods: A retrospective study was conducted utilizing a publicly available dataset comprising 100 pregnant women with a diagnosis of ICP. The ALBI score and De Ritis ratio were calculated from serum biomarkers. Univariate and multivariable logistic regression were used to assess associations, presented as odds ratios (OR) with 95% confidence intervals (CI). Predictive performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, reporting the area under the curve (AUC), sensitivity, and specificity.Results: In univariate analysis, the ALBI score was a significant predictor of adverse outcomes (OR=20.54, p<0.001), while the De Ritis ratio was not (OR=0.78, p=0.42). The ALBI score demonstrated significantly superior discriminatory power (AUC=0.712). In multivariable models adjusting for gestational age, maternal age, ALP, and GGT, the ALBI score remained a strong, independent predictor (fully adjusted OR=21.65, p=0.006), whereas the De Ritis ratio was consistently non-significant. A model combining both scores showed good predictive performance (AUC=0.714), which was significantly enhanced to an excellent level (AUC=0.845) after full adjustment for clinical covariates.Conclusion: The ALBI score is a significant and independent predictor of ICP and adverse perinatal outcomes in the pregnancy, demonstrating good prognostic utility. In contrast, the De Ritis ratio showed no meaningful predictive value. The ALBI score could serve as a useful clinical tool for risk assessment in this patient population.